CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,009 enrolled
Drug / intervention
Azelaic acid +2 moredrug
Likely dose
Azelaic acid gel 15% applied topically to affected facial areas twice daily for 12 weeks, approximately 0.5 g per 5 cm × 5 cm lesion siteAI-extracted
Key inclusion· 7
  • Healthy male or non-pregnant female ≥18 years old with clinical diagnosis of moderate facial rosacea
  • At least 8 but not more than 50 inflammatory facial lesions (papules/pustules) and ≤2 nodules on the face
  • Persistent erythema on the face with moderate (definite redness, easily recognized) to severe (marked erythema; fiery red)
  • Mild to moderate score for telangiectasia on the face
Key exclusion· 12
  • Pregnant, lactating, or planning to become pregnant during study
  • Hypersensitivity or allergy to azelaic acid, propylene glycol, or other formulation components
  • Oral retinoids (e.g., Accutane) within 6 months prior to baseline, or vitamin A supplements >10,000 units/day
  • Systemic antibiotics known to impact rosacea severity (tetracycline derivatives, erythromycin derivatives, sulfamethoxazole, trimethoprim) within 1 month prior to baseline

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02120924
NCT02120924Phase 3Completed

A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Gel, 15% and the Reference Listed Finacea® (Azelaic Acid) Gel, 15% in Patients With Moderate Facial Rosacea.

Actavis Inc.·interventional·Posted Apr 23, 2014·Updated Jun 2, 2020

In Brief

A Phase 3 clinical trial evaluating Azelaic acid, Vehicle, and 1 other intervention for Rosacea. Completed, enrolled 1,009 participants across 30 sites.

Detailed Summary

The purpose of the study is to compare the safety and efficacy profiles of a generic Azelaic Acid Gel, 15% to the reference listed Finacea® (azelaic acid) Gel, 15% in the treatment of moderate facial rosacea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 23, 2014
Enrollment StartJul 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 12.2 years ago

Interventions

Azelaic aciddrug

Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.

Vehicledrug

Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.

Finaceadrug

Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.